Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs

Kim, Kwondo; Yoo, DongAhn; Lee, Jun Young; Lee, Kyong Joo; Park, Soo Been; Kim, Chanyang; Jo, Jung Hyun; Jung, Dawoon; Song, Si Young

doi:10.1186/s12920-019-0521-8

Cited by 21 publications

(22 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, miR-128 and miR-409 are significantly downregulated, while miR-21 and miR-200 are obviously overexpressed. [38][39][40] Notably, the overexpression trend of miR-21 was consistent with the results in our study. We also found that single miR-21 alone could distinguish the malignant group from the control group and the benign group from the control group but could not distinguish the malignant group from the benign group.…”

Section: Discussionsupporting

confidence: 92%

Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer

Han

Zhang

Zhou

et al. 2021

IJGM

View full text Add to dashboard Cite

Background: Biliary tract cancers (BTCs) are aggressive malignancies with difficult early diagnosis and poor prognosis. Studies have shown that microRNAs (miRNAs) are expected to be biomarkers of the disease, which indicates that we can diagnose cancers according to the miRNAs that have significant changes. The aim of this study was to explore miRNA biomarkers of BTCs. Methods: A total of 163 samples were collected and divided into the control group, the benign group and the malignant group. High-throughput low-density chips were used to screen miRNAs with significant changes. Then, the preliminary screening test and the verification test were performed by quantitative real time PCR (qRT-PCR). Finally, the level of miRNAs in serum exosomes was measured. Results: MiR-10a, miR-21, miR-135b, miR-221, and miR-214 were upregulated in the BTCs group compared to the control group. The change in the miR-221 level was statistically significant when the malignant group was compared with the benign group (P<0.01). Meanwhile, miR-135b and miR-214 were enriched in serum exosomes. Conclusion:Five miRNAs in the serum were found to be significantly upregulated in patients with BTCs. Among them, miR-221 can serve as an early diagnostic marker for BTCs patients. MiR-10a, miR-21, miR-135b and miR-214 can be used as biomarkers for the diagnosis of biliary diseases.

show abstract

Section: Discussionsupporting

confidence: 92%

Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer

Han

Zhang

Zhou

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

“…Overexpression of miR-744-5p induced apoptosis of ovarian cancer cells and high miR-744-5p expression was associated with prolonged disease-free survival of patients with ovarian cancer ( 19 ). Additionally, the serum level of miR-744-5p was dysregulated in various types of cancers, such as pancreatic and biliary tract cancers, which indicates the potential significance of miR-744-5p in the diagnosis of cancers ( 21 ). A recent study also reported decreased expression of miR-744-5p in NSCLC ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

“…A recent study also demonstrated that miR-361 promoted the sensitivity of CRC cells to 5-fluorouracil, indicating miR-361 as a possible drug target to suppress tumorigenesis (18). Notably, recent studies revealed the significantly dysregulated expression of miR-744-5p in multiple cancers, such as hepatocellular carcinoma, gastric cancer and pancreatic cancer (19)(20)(21). Dysfunction of miR-744-5p has been suggested to play suppressive roles in the development of cancers.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑744‑5p is downregulated in colorectal cancer and targets SEPT2 to suppress the malignant phenotype

2020

View full text Add to dashboard Cite

MicroRNA (miR)-744-5p serves a pivotal role in the progression of multiple cancers; however, the function of miR-744-5p in colorectal cancer (CRC) remains largely unknown. In the present study, the effects of miR-744-5p on the progression of CRC were analyzed and the mechanisms involved were investigated. It was revealed that miR-744-5p was frequently downregulated in CRC tissues and cell lines. Overexpression of miR-744-5p significantly inhibited the proliferation, colony formation, and promoted the apoptosis of CRC cells. Bioinformatics analysis revealed that Septin 2 (SEPT2) was a potential target of miR-744-5p. miR-744-5p bound the 3′-untranslated region (UTR) of SEPT2 and reduced the level of SEPT2 in CRC cells. A negative correlation between the expression of miR-744-5p and SEPT2 was observed in CRC tissues. Overexpression of SEPT2 counteracted the suppressive effect of miR-744-5p on the proliferation and apoptosis of CRC cells. Collectively, these data demonstrated the functional mechanism of miR-744-5p by targeting SEPT2, which suggested miR-744-5p as a potential target for the treatment of patients with CRC.

show abstract

“…miR-744-5p is differentially expressed in various cancers and is involved in tumor progression. [12][13][14] Studies have indicated that miR-744-5p is lowly expressed in multiple cancers, like colorectal cancer, cervical cancer and glioblastoma, and overexpression of miR-744-5p can inhibit cell proliferation, migration, and invasion. [15][16][17] Moreover, miR-744-5p is also down-regulated in EOC cells, its upregulation could induce cell apoptosis.…”

Section: Introductionmentioning

confidence: 99%

“…And miRNAs as oncogene or anti‐oncogene have attracted more and more researchers' attention. miR‐744‐5p is differentially expressed in various cancers and is involved in tumor progression 12–14 . Studies have indicated that miR‐744‐5p is lowly expressed in multiple cancers, like colorectal cancer, cervical cancer and glioblastoma, and overexpression of miR‐744‐5p can inhibit cell proliferation, migration, and invasion 15–17 .…”

Section: Introductionmentioning

confidence: 99%

miR‐744‐5p inhibits cellular proliferation and invasion via targeting ARF1 in epithelial ovarian cancer

Zhao

Wang

Jin

et al. 2020

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

miR-744-5p has been demonstrated to play an important role in cancer progression. However, the functions of miR-744-5p in epithelial ovarian cancer (EOC) are not well clarified. In this study, our aim was to investigate the role of miR-744-5p and its underlying molecular mechanism in cell progression of EOC. EOC clinical tissues and matched adjacent ovarian epithelial tissues were collected from 18 patients. Tissues and cell lines were analyzed by qPCR or Western blot to investigate the expression of miR-744-5p and ARF1 in EOC. Cell proliferative capacity was assessed by CCK8 and colony formation assays. Wound healing and transwell assays were performed to evaluate cell migration and invasion. The potential binding relation between miR-744-5p and IRF1 was demonstrated by dual luciferase report assay. The results showed that expression of miR-744-5p was low in EOC clinical tissues and cells. Overexpression of miR-744-5p inhibited proliferation, migration, and invasion of EOC cells. Further mechanistic study identified that ARF1 is a target of miR-744-5p, which is negatively correlated with the expression of miR-744-5p, and overexpression of ARF1 could reverse the inhibition of miR-744-5p on the proliferation, migration, and invasion of EOC cells. Taken together, our results indicated that miR-744-5p attenuated EOC progression via targeting IRF1, providing potential guidance for the clinical treatment of ovarian cancer.

show abstract

Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs

Cited by 21 publications

References 58 publications

Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer

Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer

MicroRNA‑744‑5p is downregulated in colorectal cancer and targets SEPT2 to suppress the malignant phenotype

miR‐744‐5p inhibits cellular proliferation and invasion via targeting ARF1 in epithelial ovarian cancer

Contact Info

Product

Resources

About